• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 478086 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416586264 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416586264 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Possible Bearish Inside Day Candle Pattern Detected for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Published on Mon, 04/15/2013 - 07:29
By Peter Chu

Analysts have spotted a possible bearish inside day candle pattern in Spectrum Pharmaceuticals (NASDAQ:SPPI) based on the price action in the company's shares. Yesterday's price range of $7.17 and $7.29 is within the prior day's high and low of the day. This trading action often signifies indecision by bulls and bears to drive prices higher or lower and often implies a possible change in trend. Owners of Spectrum Pharmaceuticals may want to consider a possible hedge in the event a pullback occurs. Look for confirmation in the next few trading days.

Over the past year, Spectrum Pharmaceuticals has traded in a range of $6.92 to $17.48 and closed yesterday at $7.26, 5% above that low. The 200-day and 50-day moving averages have moved 1.33% lower and 4.49% lower over the past week, respectively.

Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.

Spectrum Pharmaceuticals (NASDAQ:SPPI) has potential upside of 179.9% based on a current price of $7.26 and analysts' consensus price target of $20.33. The stock should find initial resistance at its 50-day moving average (MA) of $9.86 and further resistance at its 200-day MA of $11.85.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Next Resistance Level for O'Reilly Autom...

O'Reilly Automotive (NASDAQ:ORLY) has opened bullishly above the pivot of $178.43 today ...

Stock Investors Bid Up Shares of Century...

Century Aluminum (NASDAQ:CENX) is one of today's notable stocks on the rise, up 6.2% to ...

Next Resistance Level for Ameriprise Fin...

Ameriprise Financial (NYSE:AMP) has opened bullishly above the pivot of $130.18 today a ...

Shares of Aluminum of China Receive a Bo...

One of today's stocks on the move is Aluminum of China (NYSE:ACH), up 6.3% to $11.17. ...

Next Resistance Level for DENTSPLY Inter...

Shares of DENTSPLY International (NASDAQ:XRAY) have bullishly opened above the pivot of ...

Stock Investors Bid Up Shares of Autodes...

One of today's notable stocks on the rise is Autodesk (NASDAQ:ADSK), up 6.7% to $62.33. ...

Next Resistance Level for Bemis (BMS) is...

Shares of Bemis (NYSE:BMS) opened today above their pivot of $39.12 and have already re ...

Shares of Ross Stores Receive a Boost, U...

Ross Stores (NASDAQ:ROST) is a company whose shares are active, trading 6.7% higher to ...